The R17 217.1.3-CP130 monoclonal antibody is a chimeric version of the original R17 217.1.3 antibody. The variable domain sequences are identical to the original R17 217.1.3 but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. The R17 217.1.3-CP130 antibody contains no Fc mutations just as the original rat IgG2a antibody does not. The R17 217.1.3-CP130 monoclonal antibody reacts with mouse CD71 also known as transferrin receptor protein 1 (TfR1). CD71 is a 170-180 kDa type II homodimeric transmembrane glycoprotein which is expressed on the surface of proliferating cells, reticulocytes, and erythroid precursors. CD71 plays a role in the control of cellular proliferation and is required for iron import from transferrin into cells by endocytosis. Due to its important role in proliferation and cellular iron intake as well as the fact that many cancerous cells express high levels of CD71 it is being explored as a potential new target in cases of human leukemia & lymphoma. The R17 217.1.3 antibody has been shown to deplete CD71+ erythroid splenocytes.

See the references for the original rat IgG2a R17 217.1.3 antibody (https://bioxcell.com/catalogsearch/result/?q=BP0175).